Pediatric Hematology–Oncology Research
The Division of Pediatric Hematology–Oncology at NYU Langone conducts research to determine the causes of the conditions its members treat, which include leukemia and lymphoma and brain and spinal cord tumors, and to develop more effective therapies for hematologic–oncologic and neuro-oncologic diseases. Faculty in the division are leaders in the development of clinical trials and clinical research.
The scientific faculty perform basic and translational oncology research in a rich, intellectual, and technical environment at Perlmutter Cancer Center, a National Cancer Institute–designated Comprehensive Cancer Center, and the Joan and Joel Smilow Research Center.
The division participates in combined tumor boards in sarcomas, hematologic malignancies, and neuro-oncology, bringing together a diverse and highly collaborative group of clinical and basic researchers who are engaged in the care of individuals with cancer of all ages.
The division is a member of the Children’s Oncology Group, the Neurofibromatosis Consortium, and the Pediatric Blood and Marrow Transplant Consortium.
William L. Carroll, MD, and Elizabeth A. Raetz, MD, are internationally recognized researchers in the biology and treatment of childhood acute lymphoblastic leukemia (ALL). Dr. Carroll’s laboratory focuses on the discovery of the biological pathways that mediate drug resistance in ALL. Dr. Carroll co-leads a program on the role of the epigenome in leukemia initiation and progression in Perlmutter Cancer Center and serves as the chair of the National Cancer Institute’s Pediatric Leukemia and Lymphoma Steering Committee. Recent discoveries from this lab provided insight into the nature of the clonal evolution of leukemia.
Dr. Raetz is a clinical and translational researcher who collaborates with laboratory investigators to bring discoveries to the clinic. She also serves as vice chair for the Children’s Oncology Group ALL Committee.
Jeffrey C. Allen, MD; Sharon L. Gardner, MD; and Theodore P. Nicolaides, MD, focus on novel approaches to the diagnosis and treatment of brain tumors through their nationally recognized program in pediatric neuro-oncology, which has a dedicated fellowship program. They have led several investigator-initiated clinical trials and collaborate with many other leading centers around the globe, participating in basic, translational, and clinical research in pediatric brain tumors.
Catherine S. Manno, MD, chair of the Department of Pediatrics, is a nationally renowned pediatric hematologist, recognized for her pioneering research in hemophilia B. Elizabeth A. Roman, MD, leads the hematology program, which has been expanded under her guidance. The sickle cell program has more than tripled in size during her time at NYU Langone. Dr. Roman also leads multiple quality initiatives within the program.
COMBINED BRAFV600E AND MEK INHIBITION FOR BRAFV600E-MUTANT ASTROCYTOMAS [Meeting Abstract]
Neuro-oncology. 2013 NOV; 15:60-61
Hematopoietic Stem Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group
Journal of clinical oncology. 2019 Feb 11; JCO1800884
Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies
Pediatric blood & cancer. 2018 Jan ; 65:
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL)
Blood. 2018 Mar 01; 131:995-999
MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia
Haematologica (Roma). 2018 May ; 103:830-839
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
Neuro-oncology. 2014 Oct ; 16:1408-16
Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization
Journal of clinical oncology. 2018 Oct 10; 36:2926-2934
NEW TARGETED THERAPIES FOR RELAPSED PEDIATRIC LYMPHOBLASTIC LEUKEMIA
Expert review of anticancer therapy. 2017 08 ; 17:725-736